Radioiodine and the immune system

Area of Science:

• Endocrinology
• Immunology
• Ophthalmology

Background:

• Graves' disease treatment with radioactive iodide (RAI) can alter immune responses to thyroid antigens.
• RAI therapy can lead to initial increases in thyroid-stimulating immunoglobulins and TSH receptor (TSH-R) reactivity, potentially exacerbating ophthalmopathy.
• Persistent ophthalmopathy in Graves' disease is often linked to residual thyroid tissue stimulated by thyroid-stimulating antibodies.

Purpose of the Study:

• To investigate the dualistic immune response to radioactive iodide (RAI) treatment in Graves' disease patients.
• To evaluate the efficacy of ablating residual thyroid tissue in ameliorating Graves' ophthalmopathy.

Main Methods:

• Observational study of over 40 Graves' disease patients undergoing RAI treatment.
• Comparison of ophthalmopathy severity before and after RAI ablation of residual thyroid tissue.
• Monitoring of immune response markers, including thyroid-stimulating immunoglobulins and TSH-R reactivity.

Main Results:

• Initial RAI treatment can increase immune stimulation and worsen ophthalmopathy.
• Ablation of residual thyroid tissue leads to a second phase response characterized by decreased antigenic stimulation.
• This second phase response was associated with clear amelioration of ophthalmopathy in most patients within 3-12 months.

Conclusions:

• Radioiodine ablation of residual thyroid tissue is a beneficial treatment for severe Graves' ophthalmopathy.
• This approach should be considered before or concurrently with steroids or radiotherapy for managing ophthalmopathy.
• Targeting residual thyroid tissue can reduce immune stimulation and improve outcomes in Graves' disease patients with ophthalmopathy.